Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials

Abstract Introduction Limited data exist on skin cancer risk in patients with psoriasis using biologics. Here, we report treatment-emergent adverse events (TEAEs) of skin cancer in patients treated with ixekizumab from psoriasis clinical trials. Methods Integrated safety databases from 17 clinical t...

Full description

Bibliographic Details
Main Authors: Saxon D. Smith, Alexandros Stratigos, Matthias Augustin, Jose Manuel Carrascosa, Susanne Grond, Elisabeth Riedl, Wen Xu, Himanshu Patel, Mark Lebwohl
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-06-01
Series:Dermatology and Therapy
Subjects:
Ixekizumab
Long-term
Malignancy
Melanoma
Non-melanoma skin cancer
Psoriasis
Online Access:https://doi.org/10.1007/s13555-023-00966-4

Internet

https://doi.org/10.1007/s13555-023-00966-4

Similar Items